Beck Mack & Oliver’s Biogen BIIB Stock Holding History

Beck Mack & Oliver’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-552	Closed	-$233K	–	356
2015 Q1	$233K	Buy	+552	New	+$218K	0.01%	320

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Beck Mack & Oliver's BIIB Position: Q2 2015 in Review

Beck Mack & Oliver sold out of Biogen (BIIB) in Q2 2015, closing a stake of 552 shares — an estimated $233K sold.

Beck Mack & Oliver first reported a position in BIIB in Q1 2015 and held it in 1 quarter. The position peaked at $233K in Q1 2015. 974 funds tracked by Wall St. Rank hold BIIB as of Q2 2015.

Beck Mack & Oliver reported no remaining Biogen position as of Q2 2015 after selling out during the quarter.
Beck Mack & Oliver sold 552 Biogen shares in Q2 2015, an estimated $233K.
Beck Mack & Oliver first reported a position in Biogen in Q1 2015 and held it in 1 quarter.
Beck Mack & Oliver's Biogen position peaked at $233K in Q1 2015.
974 funds tracked by Wall St. Rank held Biogen as of Q2 2015.

Based on Beck Mack & Oliver's 13F filing for Q2 2015, filed 31 Jul 2015.